Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer—a retrospective study

Although a short hydration protocol for cisplatin has been recently developed for use in lung cancer, this has yet to be established for gastric cancer. This study reviewed medical records of patients with gastric cancer who received XPT(capecitabine/cisplatin/trastuzumab) therapy containing cisplatin. Patients received either the conventional or short hydration regimen. Nephrotoxicity was compared between these two regimens by monitoring the serum creatinine. Out of the 26 total patients, 19 received the conventional regimen while 7 received the short hydration regimen. There was a higher nephrotoxicity was observed in the group receiving the conventional regimen (42.1%, 8/19) as compared to the short hydration regimen (0%, 0/7). There was a statistically significant difference in nephrotoxicity between the regimens (P = 0.039). Study results suggest that short hydration may be a feasible regimen for XPT therapy in gastric cancer patients.

[1]  T. Yamanaka,et al.  Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  H. Imamura,et al.  Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. , 2015 .

[3]  H. Ohmatsu,et al.  Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. , 2014, Japanese journal of clinical oncology.

[4]  K. Kubota,et al.  Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study. , 2013, Japanese journal of clinical oncology.

[5]  K. Kiura,et al.  Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. , 2013, Japanese journal of clinical oncology.

[6]  T. Matsuzaki,et al.  Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats , 2009, Clinical and Experimental Nephrology.

[7]  C. Szczylik,et al.  Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. , 2008, European journal of cancer.

[8]  G. Deray,et al.  Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care , 2008, Cancer Chemotherapy and Pharmacology.

[9]  M. Sormani,et al.  Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma , 2007, Tumori.

[10]  H. Hansen,et al.  Magnesium depletion enhances cisplatin-induced nephrotoxicity. , 2005, Cancer Chemotherapy and Pharmacology.

[11]  R. Coleman,et al.  Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial , 2003, Cancer Chemotherapy and Pharmacology.

[12]  N. Holstein-Rathlou,et al.  Renal tubular function in patients treated with high‐dose cisplatin , 1988, Clinical pharmacology and therapeutics.

[13]  S. Kaye,et al.  Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. , 1986, British Journal of Cancer.

[14]  W. Whitmore,et al.  Improvement of Cis‐dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model , 1977, Cancer.

[15]  J. Holland,et al.  Diaminodichloroplatinum: A phase I study showing responses in testicular and other tumors , 1974, Cancer.

[16]  K. Eguchi,et al.  Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin , 2004, Cancer Chemotherapy and Pharmacology.

[17]  J. Mansi,et al.  A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. , 1995, European journal of cancer.

[18]  L. Balducci,et al.  Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. , 1982, Cancer treatment reports.

[19]  N. Bachur,et al.  High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. , 1981, Cancer treatment reports.